A recent lightning rod for abortion opponents, the drug mifepristone—the first of two in the standard medication abortion regimen—surfaced several times during Robert F. Kennedy, Jr.’s first Senate confirmation hearing as President Trump’s pick for Health and Human Services secretary.

Robert F. Kennedy Jr had an absolute trainwreck of a confirmation hearing. Kennedy, who had been a vocal vaccine skeptic and preached numerous disproven conspiracy theories, was lambasted for his anti-science stance and his refusal to stop suing the very companies he now wants to regulate.

A higher dose of an emergency-contraception drug may open a back door for Americans seeking abortions in restrictive states.

Meanwhile, in an executive order, Trump created his long-discussed “Department of Government Efficiency,” to be led by Elon Musk, the world’s richest man. On paper, the department is tasked with modernizing federal technology and software; however, Trump and Musk have spent months boasting about how it will gut the federal government.

Last Friday, my colleague Julianne McShane and I broke the news of a pair of letters sent by 30 prominent anti-abortion movement leaders to the heads of the Departments of Health and Human Services and Justice, asking them to use the powers of their agencies to attack abortion pills.

A new study shows a possible new abortion drug to replace mifepristone. But will these results increase abortion access—or restrict women's reproductive health options down the line?

The three states argue that the FDA's approval of mifepristone for use up to 10 weeks of pregnancy, along with its availability via telemedicine and mail, has contributed to what they view as a public health risk.

A decision by a federal judge last week is reviving the effort to limit access to mifepristone, opening a fresh round of litigation over a widely used drug that has grown in importance since the ...

Those original plaintiffs dropped their case after the U.S. Supreme Court last June found they did not have the necessary legal standing to challenge the FDA’s regulation of mifepristone.

At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, which is used in abortions and miscarriages.

Robert F. Kennedy Jr. was pressed to clarify his views on vaccines, abortion, and public health priorities in his first Senate hearing.

Robert F. Kennedy Jr.’s alternating views on vaccines, reproductive rights and public health issues were a central focus at his first confirmation hearing Wednesday, with Democratic senators expressing dismay at his nomination and Republicans signaling he’ll likely have their support.